CY1120248T1 - Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου - Google Patents
Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινουInfo
- Publication number
- CY1120248T1 CY1120248T1 CY20181100532T CY181100532T CY1120248T1 CY 1120248 T1 CY1120248 T1 CY 1120248T1 CY 20181100532 T CY20181100532 T CY 20181100532T CY 181100532 T CY181100532 T CY 181100532T CY 1120248 T1 CY1120248 T1 CY 1120248T1
- Authority
- CY
- Cyprus
- Prior art keywords
- compounds
- salts
- kinolin
- cancer treatment
- description
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 206010028980 Neoplasm Diseases 0.000 title abstract 3
- 201000011510 cancer Diseases 0.000 title abstract 3
- 150000003839 salts Chemical class 0.000 abstract 8
- 102000002804 Ataxia Telangiectasia Mutated Proteins Human genes 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 108091000080 Phosphotransferase Proteins 0.000 abstract 1
- 102000001253 Protein Kinase Human genes 0.000 abstract 1
- NSHFLKZNBPJNPA-UHFFFAOYSA-N imidazo[4,5-c]quinolin-2-one Chemical class C1=CC=C2C3=NC(=O)N=C3C=NC2=C1 NSHFLKZNBPJNPA-UHFFFAOYSA-N 0.000 abstract 1
- 239000000543 intermediate Substances 0.000 abstract 1
- 230000001404 mediated effect Effects 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000020233 phosphotransferase Human genes 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 108060006633 protein kinase Proteins 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/50—Pyridazines; Hydrogenated pyridazines
- A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
Αυτή η περιγραφή αναφέρεται σε ενώσεις του Τύπου (I) και φαρμακευτικώς αποδεκτά άλατα αυτών, όπου τα Q, R1, R2, R3, R4 και R5 διαθέτουν οποιαδήποτε από τις σημασίες που ορίζονται στην παρούσα. Αυτή η περιγραφή αναφέρεται επίσης στη χρήση τέτοιων ενώσεων και άλατα αυτών για τη θεραπευτική αντιμετώπιση ή πρόληψη προκαλούμενης από ATM κινάση νόσου, συμπεριλαμβανομένου του καρκίνου. Αυτή η περιγραφή περαιτέρω αναφέρεται σε κρυσταλλικές μορφές των ενώσεων των ενώσεων ιμιδαζο[4,5- c]κινολιν-2-όνης και φαρμακευτικώς αποδεκτών αλάτων αυτών· φαρμακευτικές συνθέσεις που περιλαμβάνουν τέτοιες ενώσεις και άλατα· κιτ που περιλαμβάνουν τέτοιες ενώσεις και άλατα· μεθόδους για την παρασκευή τέτοιων ενώσεων και αλάτων· ενδιάμεσες ενώσεις χρήσιμες στην παρασκευή τέτοιων ενώσεων και αλάτων· και σε μεθόδους θεραπευτικής αντιμετώπισης προκαλούμενης από ATM κινάση πάθησης, συμπεριλαμβανομένου του καρκίνου, χρησιμοποιώντας αυτές τις ενώσεις και άλατα.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461990232P | 2014-05-08 | 2014-05-08 | |
| PCT/GB2015/051312 WO2015170081A1 (en) | 2014-05-08 | 2015-05-05 | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1120248T1 true CY1120248T1 (el) | 2019-07-10 |
Family
ID=53264681
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20181100532T CY1120248T1 (el) | 2014-05-08 | 2018-05-22 | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου |
Country Status (39)
| Country | Link |
|---|---|
| US (4) | US9428503B2 (el) |
| EP (1) | EP3140303B1 (el) |
| JP (1) | JP6505131B2 (el) |
| KR (1) | KR102013021B1 (el) |
| CN (1) | CN106255692B (el) |
| AP (1) | AP2016009532A0 (el) |
| AR (1) | AR100340A1 (el) |
| AU (1) | AU2015257456B2 (el) |
| CA (1) | CA2946459C (el) |
| CL (1) | CL2016002735A1 (el) |
| CR (1) | CR20160523A (el) |
| CY (1) | CY1120248T1 (el) |
| DK (1) | DK3140303T3 (el) |
| DO (1) | DOP2016000281A (el) |
| EA (1) | EA031674B1 (el) |
| ES (1) | ES2670416T3 (el) |
| HR (1) | HRP20180697T1 (el) |
| HU (1) | HUE037558T2 (el) |
| IL (1) | IL248397B (el) |
| LT (1) | LT3140303T (el) |
| MA (1) | MA39960A (el) |
| MX (1) | MX374401B (el) |
| NI (1) | NI201600166A (el) |
| NO (1) | NO2714752T3 (el) |
| NZ (1) | NZ726042A (el) |
| PE (1) | PE20170403A1 (el) |
| PH (1) | PH12016502168A1 (el) |
| PL (1) | PL3140303T3 (el) |
| PT (1) | PT3140303T (el) |
| RS (1) | RS57223B1 (el) |
| SG (1) | SG11201609164VA (el) |
| SI (1) | SI3140303T1 (el) |
| SM (1) | SMT201800259T1 (el) |
| SV (1) | SV2016005312A (el) |
| TN (1) | TN2016000458A1 (el) |
| TR (1) | TR201807101T4 (el) |
| TW (1) | TWI662034B (el) |
| UY (1) | UY36112A (el) |
| WO (1) | WO2015170081A1 (el) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107889488B (zh) * | 2015-04-02 | 2020-08-11 | 默克专利股份公司 | 咪唑酮基喹啉和其作为atm激酶抑制剂的用途 |
| GB201516504D0 (en) | 2015-09-17 | 2015-11-04 | Astrazeneca Ab | Imadazo(4,5-c)quinolin-2-one Compounds and their use in treating cancer |
| GB201519406D0 (en) * | 2015-11-03 | 2015-12-16 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| GB201519568D0 (en) * | 2015-11-05 | 2015-12-23 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| JP2019512512A (ja) * | 2016-03-21 | 2019-05-16 | アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ | シンノリン−４−アミン化合物およびその癌治療への使用 |
| MA44603A (fr) * | 2016-04-07 | 2019-02-13 | Astrazeneca Ab | Oxyde de n,n-diméthyl-3-[[5-(3-méthyl-2-oxo-1-tétrahydropyran-4-yl-imidazo[4,5-c]quinolin-8-yl)-2-pyridyl]oxy]propan-1-amine utilisé comme modulateur de la protéine kinase atm (ataxia telangiectasia mutated) pour traiter le cancer |
| GB201608227D0 (en) * | 2016-05-11 | 2016-06-22 | Astrazeneca Ab | Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer |
| LT3558997T (lt) | 2016-12-20 | 2021-04-26 | Astrazeneca Ab | Aminotriazolopiridino junginiai ir jų naudojimas vėžio gydymui |
| AU2018206111B2 (en) * | 2017-01-09 | 2022-07-21 | Impact Therapeutics (Shanghai), Inc | Substituted fused heteroaryl compound serving as a kinase inhibitor, and applications thereof |
| CN106798741A (zh) * | 2017-02-07 | 2017-06-06 | 宫英 | 一种治疗抑郁症的药物组合物 |
| CN106692147A (zh) * | 2017-02-07 | 2017-05-24 | 李明英 | 一种治疗男性不育的药物组合物 |
| CN106822123A (zh) * | 2017-02-09 | 2017-06-13 | 王艳苓 | 一种治疗心脑血管疾病的药物组合物 |
| US11547703B2 (en) | 2017-02-27 | 2023-01-10 | Impact Therapeutics (Shanghai), Inc | Substituted fused heteroaromatic tricyclic compounds as kinase inhibitors and the use thereof |
| JOP20190209A1 (ar) * | 2017-03-16 | 2019-09-12 | Astrazeneca Ab | مركبات إيميدازو [ 4، 5-c ] كينولين-2-أون ديوترومية واستخدامها في علاج السرطان |
| CN111344293A (zh) | 2017-09-20 | 2020-06-26 | 阿斯利康(瑞典)有限公司 | 1，3-二氢咪唑并[4，5-c]噌啉-2-酮化合物及其在治疗癌症中的用途 |
| WO2019201283A1 (en) * | 2018-04-20 | 2019-10-24 | Xrad Therapeutics, Inc. | Dual atm and dna-pk inhibitors for use in anti-tumor therapy |
| CN110386932A (zh) * | 2018-04-20 | 2019-10-29 | 艾科思莱德制药公司 | 用于抗肿瘤疗法中的双重atm和dna-pk抑制剂 |
| KR102813324B1 (ko) * | 2018-09-14 | 2025-05-26 | 수저우 잔롱 파마 리미티드 | 모세혈관확장성 운동실조증 돌연변이(ATM) 키나제의 선택적 조절제로서의 1-이소프로필-3-메틸-8-(피리딘-3-일)-1,3-디하이드로-2H-이미다조[4,5-c]신놀린-2-온 및 이의 용도 |
| CA3116234A1 (en) * | 2018-10-15 | 2020-04-23 | Merck Patent Gmbh | Combination therapy utilizing dna alkylating agents and atr inhibitors |
| WO2020178282A1 (en) * | 2019-03-05 | 2020-09-10 | Astrazeneca Ab | Fused tricyclic compounds useful as anticancer agents |
| TW202102497A (zh) * | 2019-03-29 | 2021-01-16 | 瑞典商阿斯特捷利康公司 | 化合物及它們在治療癌症中之用途 |
| CN111909147B (zh) * | 2019-05-10 | 2021-07-20 | 山东轩竹医药科技有限公司 | Dna-pk抑制剂 |
| US20220259211A1 (en) * | 2019-07-10 | 2022-08-18 | Impact Therapeutics (Shanghai), Inc | Substituted pyrazoloquinazolinone compounds and application thereof |
| KR20220062003A (ko) * | 2019-09-12 | 2022-05-13 | 임팩트 테라퓨틱스 (상하이), 인코포레이티드 | 치환된 이미다조퀴녹살린 화합물 및 이의 용도 |
| CN115003672A (zh) * | 2020-01-09 | 2022-09-02 | 南京明德新药研发有限公司 | 喹啉并咪唑类化合物及其应用 |
| US20230087844A1 (en) * | 2020-01-13 | 2023-03-23 | Shanghai Huayu Biotechnology Co., Ltd. | Use of n2-quincline or isoquinoline substituted purine derivatives in cancer treatment |
| EP4171651A1 (en) * | 2020-06-24 | 2023-05-03 | AstraZeneca UK Limited | Combination of antibody-drug conjugate and atm inhibitor |
| EP3992191A1 (en) | 2020-11-03 | 2022-05-04 | Deutsches Krebsforschungszentrum | Imidazo[4,5-c]quinoline compounds and their use as atm kinase inhibitors |
| WO2022193166A1 (en) * | 2021-03-17 | 2022-09-22 | Suzhou Zanrong Pharma Limited | Selective modulators of ataxia telangiectasia mutated (atm) kinase and uses thereof |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0211649D0 (en) * | 2002-05-21 | 2002-07-03 | Novartis Ag | Organic compounds |
| BRPI0416801A (pt) | 2003-11-21 | 2007-01-09 | Novartis Ag | derivados de 1h-imidazoquinolina como inibidores de proteìna sinase |
| GB0510390D0 (en) * | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| PE20090717A1 (es) * | 2007-05-18 | 2009-07-18 | Smithkline Beecham Corp | Derivados de quinolina como inhibidores de la pi3 quinasa |
| WO2010003025A1 (en) | 2008-07-01 | 2010-01-07 | Genentech, Inc. | Bicyclic heterocycles as mek kinase inhibitors |
| WO2010038165A1 (en) | 2008-09-30 | 2010-04-08 | Pfizer Inc. | Imidazo[1,5]naphthyridine compounds, their pharmaceutical use and compositions |
| TW201041888A (en) * | 2009-05-06 | 2010-12-01 | Plexxikon Inc | Compounds and methods for kinase modulation, and indications therefor |
| PE20120224A1 (es) | 2009-06-04 | 2012-04-04 | Novartis Ag | Derivados de 1h-imidazo-[4,5-c]-quinolinona |
| WO2010139747A1 (en) * | 2009-06-04 | 2010-12-09 | Novartis Ag | 1H-IMIDAZO[4, 5-c]QUINOLINONE COMPOUNDS, USEFUL FOR THE TREATMENT OF PROLIFERATIVE DISEASES |
| PE20140918A1 (es) * | 2009-09-28 | 2014-08-06 | Hoffmann La Roche | Compuestos de benzoxepina inhibidores de la pi3k |
| GB0919423D0 (en) | 2009-11-05 | 2009-12-23 | Glaxosmithkline Llc | Novel compounds |
| CN102199152A (zh) | 2010-03-25 | 2011-09-28 | 高大新 | 杂环咪唑类磷脂激酶抑制剂 |
| CN102372711B (zh) * | 2010-08-18 | 2014-09-17 | 山东轩竹医药科技有限公司 | 咪唑并喹啉类PI3K和mTOR双重抑制剂 |
| JPWO2012026233A1 (ja) | 2010-08-26 | 2013-10-28 | 日立建機株式会社 | 建設機械 |
| DE102010035744A1 (de) | 2010-08-28 | 2012-03-01 | Merck Patent Gmbh | Imidazolonylchinoline |
| CN102399218A (zh) * | 2010-09-16 | 2012-04-04 | 和记黄埔医药（上海）有限公司 | 一类并合三杂环及其作为pi3k抑制剂的用途 |
| KR20140014104A (ko) | 2010-12-06 | 2014-02-05 | 피라말 엔터프라이지즈 리미티드 | 치환된 이미다조퀴놀린 유도체 |
| AU2012240246A1 (en) | 2011-04-04 | 2013-05-09 | Netherlands Cancer Institute | Methods and compositions for predicting resistance to anticancer treatment with protein kinase inhibitors |
| JP6042060B2 (ja) * | 2011-09-26 | 2016-12-14 | サノフイ | ピラゾロキノリノン誘導体、その調製および治療上の使用 |
-
2012
- 2012-05-25 NO NO12793015A patent/NO2714752T3/no unknown
-
2015
- 2015-05-05 MX MX2016014639A patent/MX374401B/es active IP Right Grant
- 2015-05-05 PE PE2016002124A patent/PE20170403A1/es unknown
- 2015-05-05 SM SM20180259T patent/SMT201800259T1/it unknown
- 2015-05-05 EA EA201692095A patent/EA031674B1/ru not_active IP Right Cessation
- 2015-05-05 US US14/704,031 patent/US9428503B2/en active Active
- 2015-05-05 CA CA2946459A patent/CA2946459C/en active Active
- 2015-05-05 WO PCT/GB2015/051312 patent/WO2015170081A1/en not_active Application Discontinuation
- 2015-05-05 RS RS20180593A patent/RS57223B1/sr unknown
- 2015-05-05 PT PT157243510T patent/PT3140303T/pt unknown
- 2015-05-05 SI SI201530247T patent/SI3140303T1/en unknown
- 2015-05-05 ES ES15724351.0T patent/ES2670416T3/es active Active
- 2015-05-05 SG SG11201609164VA patent/SG11201609164VA/en unknown
- 2015-05-05 CN CN201580022454.1A patent/CN106255692B/zh active Active
- 2015-05-05 KR KR1020167034005A patent/KR102013021B1/ko active Active
- 2015-05-05 PL PL15724351T patent/PL3140303T3/pl unknown
- 2015-05-05 NZ NZ726042A patent/NZ726042A/en not_active IP Right Cessation
- 2015-05-05 AU AU2015257456A patent/AU2015257456B2/en active Active
- 2015-05-05 HR HRP20180697TT patent/HRP20180697T1/hr unknown
- 2015-05-05 HU HUE15724351A patent/HUE037558T2/hu unknown
- 2015-05-05 LT LTEP15724351.0T patent/LT3140303T/lt unknown
- 2015-05-05 AP AP2016009532A patent/AP2016009532A0/en unknown
- 2015-05-05 MA MA039960A patent/MA39960A/fr unknown
- 2015-05-05 TR TR2018/07101T patent/TR201807101T4/tr unknown
- 2015-05-05 TN TN2016000458A patent/TN2016000458A1/en unknown
- 2015-05-05 JP JP2016567002A patent/JP6505131B2/ja active Active
- 2015-05-05 CR CR20160523A patent/CR20160523A/es unknown
- 2015-05-05 DK DK15724351.0T patent/DK3140303T3/en active
- 2015-05-05 EP EP15724351.0A patent/EP3140303B1/en active Active
- 2015-05-06 UY UY0001036112A patent/UY36112A/es not_active Application Discontinuation
- 2015-05-07 AR ARP150101395A patent/AR100340A1/es not_active Application Discontinuation
- 2015-05-08 TW TW104114814A patent/TWI662034B/zh active
-
2016
- 2016-07-22 US US15/217,079 patent/US9822111B2/en active Active
- 2016-10-19 DO DO2016000281A patent/DOP2016000281A/es unknown
- 2016-10-19 IL IL248397A patent/IL248397B/en active IP Right Grant
- 2016-10-27 CL CL2016002735A patent/CL2016002735A1/es unknown
- 2016-11-02 PH PH12016502168A patent/PH12016502168A1/en unknown
- 2016-11-04 NI NI201600166A patent/NI201600166A/es unknown
- 2016-11-08 SV SV2016005312A patent/SV2016005312A/es unknown
-
2017
- 2017-10-17 US US15/785,974 patent/US10189834B2/en active Active
-
2018
- 2018-05-22 CY CY20181100532T patent/CY1120248T1/el unknown
- 2018-12-12 US US16/217,190 patent/US20190185468A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1120248T1 (el) | Ενωσεις ιμιδαζο[4,5-c]κινολιν-2-ονης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| CY1124239T1 (el) | Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου | |
| CY1124680T1 (el) | Παραγωγα 8-[6-[3-(αμινο)προποξυ]-3-πυριδυλο]-1-ισοπροπυλο-ιμιδαζο[4,5-c]κινολιν-2-ονης ως εκλεκτiκοι ρυθμιστες κινασης μεταλλαγμενης αταξιας τελαγγειεκτασιας (atm) για τη θεραπευτικη αγωγη του καρκινου | |
| CY1123627T1 (el) | Παραγωγα διυδροϊμιδαζοπυραζινονης χρησιμα στη θεραπευτικη αντιμετωπιση του καρκινου | |
| PH12018500958A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| CY1121694T1 (el) | Ενωσεις δι-κυκλικου-συντηγμενου ετεροαρυλιου ή αρυλιου και η χρηση αυτων ως αναστολεις irak4 | |
| CY1120836T1 (el) | Ενωσεις 1,3,4-θειαδιαζοαης και η χρηση τους στη θεραπευτικη αντιμετωπιση του καρκινου | |
| EA202091115A1 (ru) | Производные хиназолина, применяемые для лечения вич | |
| PH12018500957A1 (en) | Imidazo[4,5-c] quinolin -2-one compounds and their use in treating cancer | |
| EA201791304A1 (ru) | Производные изохинолина для лечения вич | |
| EA201792619A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы | |
| EA201790246A1 (ru) | Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы | |
| EA201990678A1 (ru) | Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2 | |
| MX390051B (es) | Antagonistas de ep4. | |
| CY1120602T1 (el) | [1,2,4]τριαζολο[4,3-β]πυριδαζινες για χρηση στη θεραπευτικη αντιμετωπιση πολλαπλασιαστικων ασθενειων | |
| EA201692371A1 (ru) | 1h-1,8-нафтиридин-2-оны в качестве антипролиферативных соединений | |
| EA202192822A1 (ru) | Нафтиридиновые соединения в качестве ингибиторов jak киназы |